Egyptian Pharmaceutical Journal

REVIEW ARTICLE
Year
: 2012  |  Volume : 11  |  Issue : 1  |  Page : 1--15

Schistosomiasis ( chemoprophylaxis and treatments)


Magdy I El-Zahar, Somaia El-Karim 
 Department of Therapeutical Chemistry, National Research Centre, Pharmaceutical and Drug Industries Research Division, Cairo, Egypt

Correspondence Address:
Magdy I El-Zahar
Department of Therapeutical Chemistry, National Research Centre, Pharmaceutical and Drug Industries Research Division, El-Bohowth St., P.O. Box 12622, Dokki, Cairo
Egypt

Schistosomiasis is a chronic parasitic disease affecting about 207 million individuals worldwide. It is still a major health problem in many tropical and subtropical countries, as well as for travelers from developed countries. The treatment strategies of schistosomiasis can be divided into two main routes: (a) chemotherapy treatment including trivalent antimony compounds, hycanthone mesylate, niridazole, metrifonate, oxamniquine, oltipraz, artemisinins, albendazole, amoscanate mirazid, and praziquantel; (b) vaccines that may play an important role in the control of schistosomiasis in the future.




How to cite this article:
El-Zahar MI, El-Karim S. Schistosomiasis ( chemoprophylaxis and treatments).Egypt Pharmaceut J 2012;11:1-15


How to cite this URL:
El-Zahar MI, El-Karim S. Schistosomiasis ( chemoprophylaxis and treatments). Egypt Pharmaceut J [serial online] 2012 [cited 2020 Apr 1 ];11:1-15
Available from: http://www.epj.eg.net/article.asp?issn=1687-4315;year=2012;volume=11;issue=1;spage=1;epage=15;aulast=El-Zahar;type=0